Navigation Links
Vital Therapies Initiates Liver Stabilization Trial

SAN DIEGO, Oct. 1 /PRNewswire/ -- Vital Therapies, Inc. (VTI), today announced that the first subject has been enrolled in a pivotal trial of its ELAD human cell-based liver assist system at California Pacific Medical Center (CPMC) in San Francisco. Todd Frederick, MD, Director of Liver Support Services, is the principal investigator for the trial at CPMC.

It is anticipated that up to 20 leading academic liver centers in the United States and Europe will take part in the SILVER (Stabilization In LiVER disease) study. The SILVER protocol allows for enrollment of patients with chronic liver disease who have recently suffered an acute event leading to moderate to severe liver failure, as measured by the Model for End Stage Liver Disease score (MELD). MELD score is widely accepted as an indicator of liver function.

The SILVER Trial is focusing on stabilization of liver disease so patients can either recover with their own liver intact or live long enough for a liver transplant. Liver transplantation is the only therapy proven to affect survival of liver failure patients. However the shortage of donor livers and the high cost of transplantation create a need either to support regeneration of the patient's own liver or to maintain sufficient liver function until a transplant organ becomes available. This study evaluates whether ELAD can provide this support.

For more details on the SILVER Trial, please go to

More than 120 patients have so far been treated with ELAD in six clinical trials in the United States, United Kingdom and China. An application for approval to market ELAD in China was filed in September 2007 after a pivotal clinical trial in China. This application is under review by China's SFDA.

VTI is also operating a compassionate use program with cost recovery in the United States, United Kingdom and Singapore.

About Vital Therapies, Inc. and ELAD® (Extracorporeal Liver Assist Device)

Vital Therapies, Inc. (VTI) is a privately held, venture backed company, with cell culture facilities in San Diego, California and a wholly owned subsidiary in Beijing, China. VTI is developing the first human liver cell-based Extracorporeal Liver Assist Device (ELAD) to stabilize liver function in patients with severe liver failure. During ELAD therapy the patient's plasma flows inside hollow fiber cartridges containing the cells, which process toxins and synthesize proteins and metabolites that are key products of normal human liver function. VTI completed a pivotal trial and filed for market approval of ELAD in China in September 2007. ELAD is in investigational clinical trials in the United States and Europe.

For more information go to

About California Pacific Medical Center

California Pacific Medical Center is one of the largest private, community based, not-for-profit, teaching medical centers in California and is a Sutter Health affiliate. It is a tertiary and quaternary referral center providing access to leading edge medicine while delivering the best possible personalized care. It provides a wide variety of services, including acute, post-acute and outpatient hospital care; hospice services; preventive and complementary care; and health education. Through its medical education program and research institute, physicians at California Pacific Medical Center are able to bring health care innovation to the bedside.

ELAD is a United States trademark of Vital Therapies, Inc.

SOURCE Vital Therapies, Inc.

SOURCE Vital Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sexually satisfied women have better general well-being and more vitality
2. New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical
3. Disability Advocates Call-Out Governor Schwarzenegger for Honoring Mother-In-Law While Cutting Vital Services
4. The Vitality Group Joins Efforts to Improve Health of U.S. Workforce
5. Emergency Preparedness Simulation Scenarios Developed for Disaster Training Utilizing Laerdals VitalSim(TM) Product Line
6. Frost & Sullivan: First Responders Communication Interoperability - A Vital Need for Life-Saving Services
7. Flintec Load Cell Design Helps to Create Vital Medical Solutions
8. Add Years to Your Life: Sign up for the AARP(R)/Blue Zones(R) Vitality Project to Be a Part of 6 Weeks to Longevity Kicking off on September 8th
9. Patient perception is vital when reporting medical errors
10. Vitality Health LLC Joins HealthySkinPortal Network
11. Gene vital to brains stem cells implicated in deadly brain cancer
Post Your Comments:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: